Medical professionals have long known that the earlier a disease is detected, the higher the chance for a better patient outcome.
Lexeo Therapeutics joins small class of 2023 biotech IPOs in $100M Nasdaq listing
Lexeo Therapeutics will begin trading on the Nasdaq on Friday morning via a $100 million initial public offering. The cardiac and Alzheimer’s gene therapy biotech